General American Investors Co. Inc. Sells 206,908 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

General American Investors Co. Inc. trimmed its holdings in shares of SIGA Technologies, Inc. (NASDAQ:SIGA - Free Report) by 27.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 539,738 shares of the company's stock after selling 206,908 shares during the period. General American Investors Co. Inc. owned about 0.76% of SIGA Technologies worth $3,643,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. DekaBank Deutsche Girozentrale bought a new stake in SIGA Technologies during the second quarter worth $40,000. Bayesian Capital Management LP bought a new stake in shares of SIGA Technologies in the 1st quarter valued at about $97,000. Lazard Asset Management LLC acquired a new stake in SIGA Technologies in the 1st quarter valued at about $105,000. EntryPoint Capital LLC bought a new position in SIGA Technologies during the first quarter worth about $111,000. Finally, AQR Capital Management LLC acquired a new position in SIGA Technologies during the second quarter worth approximately $99,000. Institutional investors own 55.40% of the company's stock.

SIGA Technologies Trading Down 1.2 %

Shares of SIGA traded down $0.09 during mid-day trading on Thursday, reaching $7.63. The company's stock had a trading volume of 684,170 shares, compared to its average volume of 895,581. SIGA Technologies, Inc. has a 1-year low of $4.26 and a 1-year high of $12.83. The business has a 50-day simple moving average of $7.37 and a two-hundred day simple moving average of $8.07. The stock has a market cap of $544.55 million, a P/E ratio of 6.55 and a beta of 0.89.

SIGA Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.